71 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
8 Jan 24
Regulation FD Disclosure
10:29am
23, 2023, published BMS’ 2022 ESG Report,2 providing increased transparency and disclosures 2022 Highlights Include: 58% clinical trial sites
DEFA14A
BMY
Bristol-Myers Squibb Co.
10 Apr 23
Additional proxy soliciting materials
5:12pm
of corporate governance, including taking steps to achieve greater transparency and accountability to our shareholders. As such, at 2021 Annual Meeting … transparency and accountability to our shareholders. As such, at this Annual Meeting, the Board is asking shareholders to approve an amendment
DEFA14A
n4kbmcway
20 Apr 22
Additional proxy soliciting materials
4:30pm
CORRESP
9pununa2u5lz fslsbm
18 Jan 22
Correspondence with SEC
12:00am
DEFA14A
9bggd7ld2bec
19 Apr 21
Additional proxy soliciting materials
7:41am
SC TO-C
EX-99.7
3qag03s029acs6qe
5 Oct 20
Information about tender offer
5:13pm
DEFA14A
193ujvgtutz6ejw
23 Apr 20
Additional proxy soliciting materials
8:59am
425
v8qspx jkxkzvi98fw
19 Mar 19
Business combination disclosure
7:04am
425
77iod4812
6 Mar 19
Business combination disclosure
7:03am